Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride
Author(s): Wu George, Yeung Stanley, Chen Frank
Issue: Jan/Feb 2017 - Volume 21, Number 1
View All Articles in Issue
Page(s): 76-82
Download in electronic PDF format for $75
Abstract: Neurokinin-1 receptor antagonist, 5-hydroxytryptamine-3 RA, and dexamethasone combination therapy is standard of care for the prevention of chemotherapy-induced nausea and vomiting. Herein we describe the physical and chemical stability of rolapitant injectable emulsion 166.5 mg in 92.5 mL (185 mg hydrochloride salt) admixed with palonosetron injection 0.25 mg in 5 mL (0.28 mg hydrochloride salt). Admixtures were prepared and stored in two types of container closures (110-mL Crystal Zenith plastic and glass bottles) and four types of intravenous administration sets (or intravenous tubing sets). Assessment of the physical and chemical stability was conducted on the admixtures in the ready-to-use container closure systems as supplied by the manufacturer, stored at room temperature (20°C to 25°C under fluorescent light), and evaluated at 0, 1, and 6 hours; 1 and 2 days; and under refrigeration (2°C to 8°C protected from light) after 1, 3, and 7 days. For admixtures in intravenous tubing sets, the assessment of physicochemical stability was performed after 0 and 7 hours of storage at 20°C to 25°C initially, and then after 20 hours (total 27 hours) at 2°C to 8°C protected from light. Physical stability was assessed by visual examination of the container contents under normal room light, and measuring turbidity and particulate matter. Chemical stability was assessed by measuring the pH of the admixture and determining drug concentrations and impurity levels with high-performance liquid chromatographic analysis. The results indicated that all samples were physically compatible throughout the duration of the study. The pH, turbidity, and particulate matter of the admixture stayed within narrow and acceptable ranges. Rolapitant admixed with palonosetron was chemically stable when admixed in glass and Crystal Zenith bottles for at least 48 hours at room temperature and for 7 days under refrigeration, as well as in the four selected intravenous tubing sets for 7 hours at 20°C to 25°C and then for 20 hours at 2°C to 8°C. No loss of potency of any admixed components occurred in the samples stored at the two temperature ranges and time period studied.
Related Keywords:
rolipatant, neurokinin-1 receptor antagonist, NK-1 inhibitor, 5-hydroxytryptamine-3 receptor antagonist, 5-HT3 inhibitor, palonosetron hydrochloride, drug combination, drug admixtures, chemotherapy-induced nausea and vomiting, serotonin pathway, substance P/NK-1 pathway, emesis, antiemetic agents, storage containers, intravenous tubing sets, stability, compatibility, injectable emulsion compound
Related Categories:
CANCER AND AIDS, GASTROENTEROLOGY, PARENTERALS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, STORAGE
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride
Wu George, Yeung Stanley, Chen Frank
|
Jan/Feb 2017
Pg. 76-82
|
Compatibility and Stability of Rolapitant Injectable Emulsion Admixed with Dexamethasone Sodium Phosphate
Wu George, Yeung Stanley, Chen Frank
|
Jan/Feb 2017
Pg. 66-75
|
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Granisetron Hydrochloride
Wu George, Powers Dan, Yeung Stanley, Chen Frank, Neelon Kelly
|
Jan/Feb 2018
Pg. 86-94
|
Compatibility and Stability of VARUBI (Rolapitant) Injectable Emulsion Admixed with Intravenous Palonosetron Hydrochloride Injection and Dexamethasone Sodium Phosphate Injection
Wu George, Powers Dan, Yeung Stanley, Chen Frank
|
Jan/Feb 2018
Pg. 76-85
|
Rolapitant Injectable Emulsion with Palonosetron Hydrochloride Admixture
Allen Loyd V Jr
|
Mar/Apr 2018
Pg. 151
|
Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration
Kupiec Thomas C, Ben Michel, Trusley Craig, Trissel Lawrence A
|
Mar/Apr 2008
Pg. 170-173
|
Compatibility and Stability of Palonosetron Hydrochloride with Four Neuromuscular Blocking Agents During Simulated Y-Site Administration
Trusley Craig, Ben Michel, Kupiec Thomas C, Trissel Lawrence A
|
Mar/Apr 2008
Pg. 156-160
|
Compatibility and Stability of Palonosetron Hydrochloride and Propofol During Simulated Y-Site Administration
Trissel Lawrence A, Trusley Craig, Kupiec Thomas C, Ben Michel
|
Jan/Feb 2009
Pg. 78-80
|
Compatibility and Stability of Palonosetron Hydrochloride with Lactated Ringer's, Hetastarch in Lactated Electrolyte, and Mannitol Injections During Simulated Y-Site Administration
Ben Michel, Kupiec Thomas C, Trusley Craig, Trissel Lawrence A
|
Sep/Oct 2008
Pg. 460-462
|
Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration
Ben Michel, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
|
Nov/Dec 2007
Pg. 520-524
|
Physical and Chemical Stability of Palonosetron Hydrochloride with Topotecan Hydrochloride and Irinotecan Hydrochloride during Simulated Y-Site Administration
Trissel Lawrence A, Xu Quanyun A
|
May/Jun 2005
Pg. 238-241
|
Dextromethorphan, an NMDA receptor antagonist, as a Treatment for Pain
Mishkan Emilyn S
|
Sep/Oct 2005
Pg. 339-346
|
Physical and Chemical Stability of Palonosetron Hydrochloride with Lorazepam and Midazolam Hydrochloride during Simulated Y-Site Administration
Trissel Lawrence A, Xu Quanyun A
|
May/Jun 2005
Pg. 235-237
|
Physical and Chemical Stability of Palonosetron Hydrochloride with Glycopyrrolate and Neostigmine During Simulated Y-Site Administration
Ben Michel, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
|
Jul/Aug 2008
Pg. 368-371
|
Compatibility and Stability of Aloxi (Palonosetron Hydrochloride) Admixed With Dexamethasone Sodium Phosphate
Trissel Lawrence A, Zhang Yanping
|
Sep/Oct 2004
Pg. 398-403
|
Rolapitant Injectable Emulsion with Dexamethasone Sodium Phosphate Admixture
Allen Loyd V Jr
|
May/Jun 2018
Pg. 237
|
Book Review: The NMDA Receptor
Jones Marty
|
Jan/Feb 2000
Pg. 26-27
|
Compounded Pain Formulations: What is the Evidence?
Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
|
Jul/Aug 2014
Pg. 278-286
|
Compounded Pain Formulations: What is the Evidence?
Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
|
Mar/Apr 2024
Pg. 100-109
|
Granisetron 1-mg/mL Injection
Allen Loyd V Jr
|
Jan/Feb 2013
Pg. 66
|
Return to Top |